evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

537 questions · 560 findings · 45 reviews · Common Mental Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 105 · 18.8%GRADE not reported 8 · 1.4%Very low 170 · 30.4%Low 153 · 27.3%Moderate 94 · 16.8%High 30 · 5.4%

Comparison 15: NK1 receptor antagonist GR205171 vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

It is very uncertain whether comparison 15: NK1 receptor antagonist GR205171 changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).

1 finding from 1 review

Levetiracetam vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

Comparison 3: anticonvulsant levetiracetam showed no clear difference in global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (moderate certainty).

1 finding from 1 review

Vortioxetine vs placebo

Response · adults with Major Depressive Disorder

Vortioxetine may leads to higher response compared with placebo (low certainty).

1 finding from 1 review

Vortioxetine vs placebo

Total number of drop‐outs · adults with Major Depressive Disorder

Vortioxetine showed no clear difference in total number of drop‐outs compared with placebo (moderate certainty).

1 finding from 1 review

Vortioxetine vs placebo

Remission · adults with Major Depressive Disorder

Vortioxetine may leads to higher remission compared with placebo (low certainty).

1 finding from 1 review

Vortioxetine vs placebo

Adverse effects (drop‐outs due to adverse effects4) · adults with Major Depressive Disorder

Vortioxetine probably leads to higher drop‐out due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Vortioxetine vs placebo

Drop out due to inefficacy Number of participants who dropped out due to inefficacy during the trial, as a proportion of the total number of randomised participants · adults with Major Depressive Disorder

Vortioxetine probably leads to lower drop‐out due to inefficacy compared with placebo (moderate certainty).

1 finding from 1 review

Vortioxetine vs placebo

Tolerability · adults with Major Depressive Disorder

Vortioxetine probably leads to higher tolerability compared with placebo (moderate certainty).

1 finding from 1 review

Topiramate vs placebo

Efficacy: change in scores from baseline to endpoint (12 weeks) on symptom rating scales in the treatment of manic and mixed episodes Lower scores indicate improvement · adults with acute affective episodes in bipolar disorder
2 findings from 1 review

Topiramate as add‐on therapy vs placebo

Acceptability. Participants experiencing troublesome adverse effects of any nature · adults with acute affective episodes in bipolar disorder

Topiramate as add‐on therapy showed no clear difference in acceptability with topiramate (endpoint: 12 weeks) Number of… compared with placebo (low certainty).

1 finding from 1 review

Topiramate as add‐on therapy vs placebo

Response to treatment with topiramate. Number of participants experiencing a 50% reduction or greater in mean score from baseline to end of treatment on symptom rating scales in manic and mixed episodes · adults with acute affective episodes in bipolar disorder

Topiramate as add‐on therapy showed no clear difference in response to treatment with topiramate. Number of participants… compared with placebo (low certainty).

1 finding from 1 review